Five questions healthcare leaders should ask about compliance oversight, executive accountability, data analytics, and organizational culture.
On October 1, 2026, the U.S. Department of Justice (DOJ) Fraud Division issued Directive 26-12, Corporate Enforcement in the Fight Against Fraud, reinforcing the government’s commitment to aggressive fraud enforcement while emphasizing the importance of voluntary disclosure, cooperation, and remediation. The directive provides valuable insight into how prosecutors will evaluate corporate conduct and allocate enforcement resources in the years ahead.
DOJ Directive 26-12 does not create new healthcare compliance obligations. Instead, it highlights factors prosecutors may consider in corporate fraud matters, including management accountability, voluntary disclosure, cooperation, remediation, data analytics, and whistleblower reporting.
For healthcare organizations, the directive should be viewed as more than an enforcement announcement. It offers a window into the factors DOJ is likely to consider when assessing organizational misconduct, management accountability, compliance oversight, and corrective action efforts.
Notably, the directive identifies healthcare fraud, controlled-substance-related offenses, and violations of the Federal Food, Drug, and Cosmetic Act among the Fraud Division’s enforcement priorities. It also underscores DOJ’s continued focus on management involvement, corporate accountability, fraud detection, and whistleblower reporting.
As healthcare organizations prepare for an increasingly sophisticated enforcement environment, five questions deserve particular attention:
1. Is Executive Leadership Demonstrating Meaningful Compliance Oversight?
Perhaps the most significant takeaway for healthcare leaders is DOJ’s continued focus on management accountability. The directive instructs prosecutors to place substantial weight on whether corporate management knew of or participated in a fraud scheme. It further highlights efforts to conceal misconduct and conduct that persists over an extended period as important enforcement considerations.
These factors reinforce a fundamental compliance principle: Leadership oversight matters.
Organizations should evaluate whether executives and governing boards receive meaningful information regarding compliance risks, investigations, corrective actions, and emerging trends. Effective oversight requires more than periodic reporting. Leaders should understand the organization’s most significant compliance risks, critically evaluate the information and conclusions presented to them, and ensure appropriate action is taken when concerns arise.
As regulators increasingly expect accountability throughout the leadership structure, organizations cannot delegate compliance matters solely to the compliance officer.
2. Could We Demonstrate Our Compliance Efforts to Regulators?
The directive reaffirms DOJ’s commitment to crediting organizations that disclose misconduct, cooperate with government investigations, and undertake meaningful remediation. Prosecutors are directed to apply the Department’s Corporate Enforcement and Voluntary Self-Disclosure Policy when evaluating corporate matters.
As a result, healthcare organizations should ask a fundamental question:
If regulators arrived tomorrow, could we demonstrate how our compliance program identified, escalated, investigated, and addressed significant risks?
Organizations should be prepared to demonstrate
- Effective compliance oversight
- Timely identification of compliance concerns
- Objective and well-documented investigations
- Appropriate corrective action
- Sustainable remediation efforts
- Continuous program improvement
When enforcement matters arise, regulators often evaluate the underlying misconduct and the organization’s response once concerns were identified.
3. Are We Focused on the Right Risks?
The memorandum specifically directs prosecutors to prioritize fraud schemes involving the healthcare industry, including healthcare fraud, controlled substances, and violations of the Federal Food, Drug, and Cosmetic Act.
Accordingly, healthcare organizations should periodically reassess whether compliance resources are aligned with the areas presenting the greatest regulatory and operational exposure.
High-risk areas commonly include
- Billing and coding compliance
- Physician arrangements and referral relationships
- Controlled substance oversight
- Research compliance
- Revenue cycle integrity
- Government reimbursement programs
- Third-party and vendor relationships
- Patient safety and quality-related compliance risks
Risk assessments should not be static exercises performed to satisfy regulatory expectations.
They should help leadership understand where misconduct is most likely to occur and where monitoring, auditing, and compliance resources will have the greatest impact.
4. Are We Leveraging Data as Effectively as Regulators?
One of the most notable aspects of the directive is DOJ’s emphasis on technology and data analytics. The memorandum specifically references the National Fraud Detection Center and the government’s use of advanced analytics and technology to proactively identify potential fraud and generate investigative leads.
Healthcare organizations should view this as an important signal.
Regulators are deploying sophisticated tools capable of identifying reimbursement anomalies, outlier billing patterns, referral relationships, prescribing trends, and other indicators of potential misconduct.
A practical question for every compliance program is
If regulators can identify a risk through analytics, can we?
Depending on their risk profile and resources, healthcare organizations may incorporate
- Compliance dashboards
- Claims and reimbursement analytics
- Open Payments monitoring
- Exclusion screening oversight
- Third-party risk analytics
- Continuous monitoring
- Data-informed auditing strategies
Used appropriately, compliance analytics can strengthen an organization’s ability to identify anomalies, prioritize reviews, and direct monitoring resources.
5. Would Employees Raise Concerns Internally Before Going to the Government?
The directive also highlights DOJ’s intention to develop and enhance programs that incentivize whistleblowers to report credible information related to fraud, including individuals who may have participated in the underlying misconduct themselves.
This development further elevates the importance of organizational culture.
Employees, physicians, contractors, and vendors are more likely to raise concerns internally when they trust the compliance function, believe reports will be investigated fairly, and have confidence that retaliation will not occur. Conversely, when trust is lacking, organizations may lose the opportunity to address concerns before they reach government investigators.
Healthcare organizations should assess whether
- Reporting mechanisms are accessible and trusted
- Investigations are timely and objective
- Employees understand how to raise concerns
- Anti-retaliation protections are effective
- Leadership consistently reinforces ethical expectations
A strong culture of compliance can help an organization identify and address issues before they become significant regulatory matters.
How Healthcare Organizations Should Respond to DOJ Directive 26-12
The directive does not establish new compliance requirements. However, it reinforces several themes that should already be familiar to healthcare organizations committed to compliance excellence.
Healthcare leaders should consider
- Reassessing compliance program effectiveness through a risk-based lens
- Evaluating whether boards and executive leaders receive meaningful compliance intelligence
- Revisiting enterprise risk assessments and high-risk operational areas
- Expanding the use of analytics and continuous monitoring
- Reviewing investigation, escalation, and remediation processes
- Strengthening efforts to foster a culture of accountability and compliance
What the Directive Means for Healthcare Compliance Programs
DOJ’s latest directive reinforces a trend healthcare organizations have been experiencing for years: Enforcement agencies increasingly expect organizations to identify and address risk before regulators do.
Organizations that can demonstrate strong governance, proactive risk identification, data-driven monitoring, effective investigations, and meaningful remediation will be better positioned when regulatory scrutiny arises. Conversely, organizations that rely on compliance programs that exist primarily on paper may find it increasingly difficult to withstand government review.
For healthcare leaders, the question is no longer whether a compliance program exists. The more important question is whether the program provides meaningful insight into organizational risk and enables leadership to make informed decisions before problems become enforcement matters.
Amid heightened enforcement, advanced analytics, and expanding whistleblower incentives, compliance effectiveness is demonstrated not only by policies and procedures but also by an organization’s ability to identify risks, respond decisively, and demonstrate accountability when it matters most.
How PYA Can Help
PYA’s Healthcare Compliance and Litigation Support experts partner with organizations to navigate compliance scrutiny related to potential fraud. With a wide range of compliance expertise and healthcare industry experience, we work alongside external counsel, organizational leadership, compliance teams, and front-line staff to develop sustainable compliance programs, assess risk, investigate concerns, quantify potential exposure, and develop defensible paths forward.
Source: U.S. Department of Justice Fraud Division, Directive 26-12, Corporate Enforcement in the Fight Against Fraud (Oct. 1, 2026).
